However, despite these uncertainties when quantifying risk of SGLT-2 inhibition, the absolute excess risk of ketoacidosis and amputation was clearly about an order of magnitude smaller than the absolute benefits on cardiac and renal outcomes in people with type 2 DM at high ASCVD risk or with CKD, and the absolute cardiac benefits were nearer two orders of magnitude greater in people with HF. The gene discussed is SLC5A2; the disease is chronic kidney disease.